Driveitaway Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Driveitaway Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $987.9K | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $461.0K | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | $307.3K | Feb 24, 2025 |
| FY2023 | Sep 30, 2022 | $55.5K | Mar 8, 2024 |
| FY2022 | Sep 30, 2021 | $118.6K | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | $3.04M | Jan 11, 2022 |
| FY2020 | Sep 30, 2019 | $4.52M | Dec 30, 2020 |
| FY2019 | Sep 30, 2018 | $2.42M | Apr 1, 2020 |
| FY2018 | Sep 30, 2017 | $2.46M | Sep 4, 2019 |
| FY2016 | Sep 30, 2016 | $3.24M | Dec 22, 2016 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $2.46M | Jan 4, 2018 |
| FY2017 | Sep 30, 2016 | $3.24M | Jan 4, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $135.7K | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $138.3K | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | $68.5K | Feb 24, 2025 |
| FY2023 | Sep 30, 2022 | $16.6K | Mar 8, 2024 |
| FY2022 | Sep 30, 2021 | $80.8K | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | $3.04M | Jan 11, 2022 |
| FY2020 | Sep 30, 2019 | $4.52M | Dec 30, 2020 |
| FY2019 | Sep 30, 2018 | $2.41M | Apr 1, 2020 |
| FY2018 | Sep 30, 2017 | $2.46M | Sep 4, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Sep 30, 2023 | ($930.1K) | Mar 8, 2024 |
| FY2023 | Sep 30, 2022 | ($1.48M) | Mar 8, 2024 |
| FY2022 | Sep 30, 2021 | ($675.7K) | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | $620.2K | Jan 11, 2022 |
| FY2019 | Dec 31, 2019 | $2.02M | Apr 1, 2020 |
| FY2020 | Sep 30, 2019 | $2.02M | Dec 30, 2020 |
| FY2019 | Dec 31, 2018 | ($218.8K) | Apr 1, 2020 |
| FY2019 | Sep 30, 2018 | ($218.8K) | Apr 1, 2020 |
| FY2018 | Sep 30, 2017 | ($1.03M) | Sep 4, 2019 |
| FY2017 | Sep 30, 2016 | ($1.82M) | Jan 4, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($868.5K) | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | ($568.2K) | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | ($762.5K) | Feb 24, 2025 |
| FY2023 | Sep 30, 2022 | ($1.19M) | Mar 8, 2024 |
| FY2022 | Sep 30, 2021 | ($661.1K) | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | $585.5K | Jan 11, 2022 |
| FY2020 | Sep 30, 2019 | $1.95M | Dec 30, 2020 |
| FY2019 | Sep 30, 2018 | ($215.1K) | Apr 1, 2020 |
| FY2018 | Sep 30, 2017 | ($692.5K) | Sep 4, 2019 |
| FY2017 | Sep 30, 2016 | ($2.40M) | Jan 4, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $113.4K | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $39.2K | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | $56.5K | Feb 24, 2025 |
| FY2023 | Sep 30, 2022 | $61.5K | Mar 8, 2024 |
| FY2022 | Sep 30, 2021 | $81.2K | Jan 13, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($477.7K) | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | ($424.4K) | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | ($445.1K) | Feb 24, 2025 |
| FY2023 | Sep 30, 2022 | ($827.6K) | Mar 8, 2024 |
| FY2022 | Sep 30, 2021 | ($239.8K) | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | ($306.2K) | Jan 11, 2022 |
| FY2020 | Sep 30, 2019 | $397.9K | Dec 30, 2020 |
| FY2019 | Sep 30, 2018 | ($25.9K) | Apr 1, 2020 |
| FY2018 | Sep 30, 2017 | ($50.4K) | Sep 4, 2019 |
| FY2017 | Sep 30, 2016 | ($2.12M) | Jan 4, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2022 | $157.9K | Jan 13, 2023 |
| FY2021 | Sep 30, 2021 | $3.2K | Jan 11, 2022 |
| FY2020 | Sep 30, 2019 | $118.8K | Dec 30, 2020 |
| FY2019 | Sep 30, 2018 | $192.6K | Apr 1, 2020 |
| FY2018 | Sep 30, 2017 | $19.3K | Sep 4, 2019 |
| FY2017 | Sep 30, 2016 | $69.1K | Jan 4, 2018 |
| FY2016 | Sep 30, 2015 | $7.9K | Dec 22, 2016 |
| FY2015 | Sep 30, 2014 | $118.3K | Sep 13, 2016 |
| FY2014 | Sep 30, 2013 | $26.0K | Mar 31, 2015 |
| FY2013 | Sep 30, 2012 | $144.4K | Jun 5, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $680.3K | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $1.07M | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | $230.8K | Feb 24, 2025 |
| FY2023 | Sep 30, 2022 | $293.1K | Mar 8, 2024 |
| FY2022 | Sep 30, 2021 | $31.2K | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | $1.59M | Jan 11, 2022 |
| FY2020 | Sep 30, 2019 | $2.16M | Dec 30, 2020 |
| FY2019 | Sep 30, 2018 | $745.3K | Apr 1, 2020 |
| FY2018 | Sep 30, 2017 | $1.12M | Sep 4, 2019 |
| FY2017 | Sep 30, 2016 | $2.05M | Jan 4, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $9.18M | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $5.03M | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | $2.19M | Feb 24, 2025 |
| FY2023 | Sep 30, 2022 | $1.39M | Mar 8, 2024 |
| FY2022 | Sep 30, 2021 | $516.6K | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | $3.41M | Jan 11, 2022 |
| FY2020 | Sep 30, 2019 | $4.60M | Dec 30, 2020 |
| FY2019 | Sep 30, 2018 | $273.0K | Apr 1, 2020 |
| FY2015 | Sep 30, 2015 | $897.6K | Sep 13, 2016 |
| FY2015 | Sep 30, 2014 | $874.6K | Sep 13, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($8.50M) | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | ($3.96M) | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | ($1.95M) | Feb 24, 2025 |
| FY2023 | Sep 30, 2022 | ($1.10M) | Mar 8, 2024 |
| FY2023 | Sep 30, 2021 | ($485.4K) | Mar 8, 2024 |
| FY2022 | Sep 30, 2020 | ($219.1K) | Jan 13, 2023 |
| FY2019 | Dec 31, 2019 | ($2.44M) | Apr 1, 2020 |
| FY2021 | Sep 30, 2019 | ($2.44M) | Jan 11, 2022 |
| FY2019 | Dec 31, 2018 | $472.3K | Apr 1, 2020 |
| FY2020 | Sep 30, 2018 | $472.3K | Dec 30, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($10.46M) | Jan 13, 2026 |
| FY2023 | Sep 30, 2023 | ($3.31M) | Mar 8, 2024 |
| FY2023 | Sep 30, 2022 | ($2.38M) | Mar 8, 2024 |
| FY2022 | Sep 30, 2021 | ($905.4K) | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | ($4.77M) | Jan 11, 2022 |
| FY2020 | Sep 30, 2019 | ($5.39M) | Dec 30, 2020 |
| FY2019 | Sep 30, 2018 | ($2.39M) | Apr 1, 2020 |
| FY2018 | Sep 30, 2017 | ($2.17M) | Sep 4, 2019 |
| FY2017 | Sep 30, 2016 | ($1.14M) | Jan 4, 2018 |
| FY2016 | Sep 30, 2015 | $676.4K | Dec 22, 2016 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $39.9K | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | $33.6K | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | $4.6K | Feb 24, 2025 |
| FY2023 | Sep 30, 2022 | $127.1K | Mar 8, 2024 |
| FY2022 | Sep 30, 2021 | $9.8K | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | $427.7K | Jan 11, 2022 |
| FY2020 | Sep 30, 2019 | $522.1K | Dec 30, 2020 |
| FY2019 | Sep 30, 2018 | $80.7K | Apr 1, 2020 |
| FY2018 | Sep 30, 2017 | $214.0K | Sep 4, 2019 |
| FY2018 | Sep 30, 2016 | $276.7K | Sep 4, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Sep 30, 2023 | 0 | Mar 8, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Mar 8, 2024 |
| FY2021 | Sep 30, 2021 | 0 | Jan 11, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Jan 11, 2022 |
| FY2020 | Sep 30, 2019 | 0 | Dec 30, 2020 |
| FY2017 | Sep 30, 2017 | 0 | Jan 4, 2018 |
| FY2017 | Sep 30, 2016 | 0 | Jan 4, 2018 |
| FY2016 | Sep 30, 2015 | 0 | Dec 22, 2016 |
| FY2015 | Sep 30, 2014 | 0 | Sep 13, 2016 |
| FY2014 | Sep 30, 2013 | 0 | Mar 31, 2015 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Sep 30, 2023 | 0 | Mar 8, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Mar 8, 2024 |
| FY2021 | Sep 30, 2021 | 0 | Jan 11, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Jan 11, 2022 |
| FY2020 | Sep 30, 2019 | 0 | Dec 30, 2020 |
| FY2015 | Sep 30, 2015 | 0 | Sep 13, 2016 |
| FY2015 | Sep 30, 2014 | 0 | Sep 13, 2016 |
| FY2014 | Sep 30, 2013 | 0 | Mar 31, 2015 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 120.01M | Jan 13, 2026 |
| FY2025 | Sep 30, 2024 | 113.69M | Jan 13, 2026 |
| FY2024 | Sep 30, 2023 | 106.54M | Feb 24, 2025 |
| FY2023 | Sep 30, 2022 | 105.29M | Mar 8, 2024 |
| FY2022 | Sep 30, 2021 | 0 | Jan 13, 2023 |
| FY2021 | Sep 30, 2020 | 13.30M | Jan 11, 2022 |
| FY2020 | Sep 30, 2019 | 13.54M | Dec 30, 2020 |
| FY2019 | Sep 30, 2018 | 12.01M | Apr 1, 2020 |
| FY2018 | Sep 30, 2017 | 12.01M | Sep 4, 2019 |
| FY2017 | Sep 30, 2016 | 12.00M | Jan 4, 2018 |